Guanfacine for Treatment of Attention-Deficit Hyperactivity Disorder in Boys
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The use of guanfacine hydrochloride (Tenex), a long-acting alpha2 agonist with a more favorable side effect profile relative to clonidine, was examined in boys with ADHD. In this prospective, open-label, non-blinded trial, guanfacine was prescribed to fifteen boys, aged 7 to 17 years old (mean 13.3 years) for 5-10 weeks (mean 8 weeks). Thirteen of the boys were on guanfacine monotherapy, while two were on a single adjunctive agent (with the dose of the latter unchanged during the trial). Rating scales were completed before the start of the guanfacine trial and at 4 to 8 weeks after the dose was stabilized. In general, the guanfacine appeared to be effective in reducing the target symptoms, with minimal side effects. The dose of guanfacine ranged from 0.5 mg to 3 mg daily (with a mode of 0.5 mg bid, and a mean of 1.27 mg daily). In the 13 subjects who completed the trial, the mean decrease in the Conners Parent-Teacher Scale (Short Form) was 11.1 points (t = 7.18, p < 0.0001), while the mean decrease in the Edelbrock CAP inattention subscale was 4.85 (t = 5.94, p < 0.0001) and in the overactivity subscale 3.23 (t = 5.93, p < 0.0001). Two of the patients discontinued the medication, one due to clinical ineffectiveness and one due to apparent overactivation. The findings suggest that guanfacine may be a useful agent in the management of a number of the core features of ADHD. Further studies with a double-blinded placebo-controlled design appear indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391
Clonidine in Child and Adolescent Psychiatry
HUNT, R. D., CAPPER, L., & O'CONNELL, P. (1990) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1990.1.87 · Cited by 127
Cited by
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Tourette syndrome, associated conditions and the complexities of treatment
Robertson, M. M. (2000) · Brain · doi:10.1093/brain/123.3.425 · Cited by 704
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
Adrenergic pharmacology and cognition: Focus on the prefrontal cortex
Ramos, B. P., & Arnsten, A. F. T. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.006 · Cited by 641
Dulcan, M. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199710001-00007 · Cited by 628
Catecholamine modulation of prefrontal cortical cognitive function
Arnsten, A. F. T. (1998) · Trends in Cognitive Sciences · doi:10.1016/s1364-6613(98)01240-6 · Cited by 604
Advances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
Scahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., Arnsten, A. F. T., Cohen, D. J., & Leckman, J. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1067 · Cited by 588
Attention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder
Biederman, J., & Spencer, T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00192-4 · Cited by 513
Catecholamine regulation of the prefrontal cortex
Arnsten, A. F. T. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100208 · Cited by 488
Arnsten, A. F. T. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050084013 · Cited by 458
Jankovic, J. (2001) · New England Journal of Medicine · doi:10.1056/nejmra010032 · Cited by 447
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317
Arnsten, A. F., Scahill, L., & Findling, R. L. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0098 · Cited by 307
Contemporary assessment and pharmacotherapy of Tourette syndrome
Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B. J., Jankovic, J., Kiessling, L., King, R. A., Kurlan, R., Lang, A., et al. (2006) · NeuroRX · doi:10.1016/j.nurx.2006.01.009 · Cited by 300
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A. (2008) · CNS Spectrums · doi:10.1017/s1092852900017107 · Cited by 270
Spencer, T. J., Greenbaum, M., Ginsberg, L. D., & Murphy, W. R. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0152 · Cited by 257
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder
Biederman, J., Spencer, T., & Wilens, T. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003973 · Cited by 253
Through the looking glass: Differential noradenergic modulation of prefrontal cortical function
Arnsten, A. F. T. (2000) · Neural Plasticity · doi:10.1155/np.2000.133 · Cited by 229
Franowicz, J. S., Kessler, L. E., Borja, C. M. D., Kobilka, B. K., Limbird, L. E., & Arnsten, A. F. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08771.2002 · Cited by 185
Non?stimulant medications in the treatment of ADHD
Banaschewski, T., Roessner, V., Dittmann, R. W., Janardhanan Santosh, P., & Rothenberger, A. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1010-x · Cited by 183
“The literature on guanfacine is more limited [37, 80, 83, 140, 166].”
BackgroundLi, B. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00070-6 · Cited by 162
“…experimentally or clinically for the treatment of human psychiatric disorders such as schizophrenia (Fields et al. 1988), Korsakoff’s syndrome (Mair and McEntee 1986), and especially Attention Deficit Hyperactivity Disorder (Hunt et al. 1985, 1995; Chappell et al. 1995; Horrigan and Barnhill 1995).”
BackgroundMethodInfluentialGuanfacine in children with autism and/or intellectual disabilities
Handen, B. L., Sahl, R., & Hardan, A. Y. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181739b9d · Cited by 126
Locomotor hyperactivity induced by blockade of prefrontal cortical α2-adrenoceptors in monkeys
Ma, C.-L., Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.004 · Cited by 96
Steere, J. C., & Arnsten, A. F. T. (1997) · Behavioral Neuroscience · doi:10.1037/0735-7044.111.5.883 · Cited by 94
Birnbaum, S. G., Podell, D. M., & Arnsten, A. F. T. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00306-3 · Cited by 81
Prince, J. B. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.002 · Cited by 76
“A clonidine-like but more selective alpha-2 adrenergic agonist compound, guanfacine, has been used as an alternative to clonidine for the same indications [93,94].”
Lack of effects of guanfacine on executive and memory functions in healthy male volunteers
Müller, U., Clark, L., Lam, M. L., Moore, R. M., Murphy, C. L., Richmond, N. K., Sandhu, R. S., Wilkins, I. A., Menon, D. K., Sahakian, B. J., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0078-4 · Cited by 73
Ma, C.-L., Qi, X.-L., Peng, J.-Y., & Li, B.-M. (2003) · NeuroReport · doi:10.1097/01.wnr.0000070831.57864.7b · Cited by 69
Newcorn, J. H., Schulz, K., Harrison, M., DeBellis, M. D., Udarbe, J. K., & Halperin, J. M. (1998) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70064-x · Cited by 68
ADHD in Children, Adolescents, and Adults
Katragadda, S., & Schubiner, H. (2007) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2007.04.012 · Cited by 61
Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness
Scahill, L. (2009) · CNS Drugs · doi:10.2165/00023210-200923000-00006 · Cited by 58
Drug and non-drug treatments of children with ADHD and tic disorders
Poncin, Y., Sukhodolsky, D. G., McGuire, J., & Scahill, L. (2007) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-007-1010-8 · Cited by 37
Wang, M., Tang, Z.-X., & Li, B.-M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.062 · Cited by 31
Faraone, S. V., & Glatt, S. J. (2010) · Journal of Attention Disorders · doi:10.1177/1087054709332472 · Cited by 30
Swartz, B. E., McDonald, C. R., Patel, A., & Torgersen, D. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181633461 · Cited by 20
Metadata
- Authors
- HORRIGAN, J. P., & BARNHILL, L. J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1995-01
- Volume
- 5
- Issue
- 3
- Pages
- 215-223
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2039755273
- Cited by
- 117
- References
- 2
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.